The heterodimeric ol4 integrins c~4~7 lymphocyte Peyer's patch adhesion molecule ([LPAM]-I) and ol431 (very late antigen-4) are cell surface adhesion molecules involved in lymphocyte trafficking and lymphocyte-cell and matrix interactions. Known cellular ligands include vascular cell adhesion molecule (VCAM)-I, which binds to ~431 and ol437, and the mucosal addressin cell adhesion molecule (MAdCAM)-I, which binds to ol437. Here we show that the o~4 chain of these integrins can itself serve as a ligand. The c~4 chain, immunoaffinity purified and immobilized on glass slides, binds thymocytes and T lymphocytes. Binding exhibits divalent cation requirements and temperature sensitivity which are characteristic of integrin-mediated interactions, and is specifically inhibited by anti-cx4 integrin antibodies, which exert their effect at the cell surface. Cells expressing exclusively c~4/~7 (TK-1) or c~431 (L1-2) both bound avidly, whereas ol4-negative cells did not. A soluble 34-kD ol4 chain fragment retained binding activity, and it inhibited lymphocyte adhesion to ~4 ligands. It has been shown that c~4 integrin binding to fibronectin involves an leucine-aspartic acid-valine (LDV) motif in the HeplI/IIICS region of fibronectin (CS-1 peptide), and homologous sequences are important in binding to VCAM-1 and MAdCAM-1. Three conserved LDV motifs occur in the extracellular sequence of c~4. A synthetic LDV-containing c~4-derived oligopeptide supports c~4-integrin-dependent lymphocyte adhesion and blocks binding to the 34-kD ol4 chain fragment. Our results suggest that r and r integrins may be able to bind to the ol4 subunit on adjacent cells, providing a novel mechanism for ol4 integrin-mediated and activation-regulated lymphocyte interactions during immune responses.
terligand(s) for c~4 integrins or, alternatively, that or4 integrins are capable of interacting in a homotypic fashion.
Here we report that the isolated oe4 integrin chain itself, as well as leucine-aspartic acid-valine (LDV)-containing peptides of oe4, can serve as ligands for recognition and binding by lymphocytes oe4B1 and oe4f17. Our results suggest a novel c~4-c~4 binding mechanism that could participate in diverse o~4-dependent cell-cell interactions.
Materials and Methods
Cell Culture. The murine bend3 endothelioma cell line was kindly provided by Dr. W. Risau (Bad Nauheim, FRG) and was maintained in DMEM with high glucose (Life Technologies, Eggenstein, FRG) containing 10% low endotoxin fetal bovine serum (FBS) (Life Technologies). Cells were activated with LPS from Salmonella enteritidis (Sigma, Deisenhofen, FRG) at a dose of 1 #g/ml for 4 h at 37~ The T cell lymphoma line TK-1 (13, 27) , the lymphoma cell lines ESb 289 and Eb (28) , and the B lymphoma line L1-2 were maintained in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 10 mM Hepes, and 50 mM 2-ME (culture medium). The T cell hybridoma cell line BI 141 (29) was kindly provided by A. Reske-Kunz (University of Mainz, Mainz, FRG) and was maintained in Iscove's medium supplemented with 5% FBS, sodium pyruvate, and 50 mM 2-ME. All cells were kept at 37~ 5% CO2, and 100% humidity. Spleen and thymus cells were collected from 6-8-wk-old DBA/2 mice. Erythrocytes were lysed by brief incubation in 155 mM NH4C1, 0.1 mM EDTA, 10 mM KHCO5 solution. T lymphocytes were purified from spleen by passage over nylon wool followed by treatment with B220 mAb RA32C2 (30) and rabbit complement (Camon, Wiesbaden, FRG). T lymphoblasts were induced from splenic lymphocytes by activation with 5 /zg/ml Con A in RPMI 1640 supplemented with 10% FBS and 50 mM 2-ME for 48 h. Blast cells were purified by Percoll centrifugation (Pharmacia, Freiburg, FRG) and cell clumps were dissociated by treatment with PBS containing 5 mM EDTA.
Antibodies. The mAb 5/3 was obtained by immunizing rats with bend3 cells stimulated for 4 h with LPS. Animals were injected subcutaneously with live cells (1-2 x 107 per injection) in PBS and four booster injections were given with 2-wk intervals. Spleen cells from these rats were fused with Sp2/0 cells as described (31) and hybridomas that were able to block the binding of thymocytes to LPS-activated bend3 cells were selected, mAb 5/3 (IgG2b) was obtained from the parental blocking subclone 228/10 by limiting dilution cloning, mAb 7/1 (IgM) was obtained from the same subclone and has no blocking potential. It recognizes a cell surface molecule with unknown function and was used for control purposes. Other mAbs were: PS/2 (32) and R1-2 (13) directed against c~4 integrins, FD441 (TIB 213) and FD 18.5 (33) recognizing the c~ chain of LFA-1, 30G12 against mouse CD45, MK2.7 against VCAM-1 (34), YN.1/1.7 against intracellular adhesion molecule-1 (ICAM-1) (35), 12-15 against mouse CD2 (36) , DATK-32 against a combinational epitope of oe437 (17) , -Fib 30 against 37 (15) , 324 against the L1 adhesion molecule (37) , and 79 against HSA (38) .
Peptides. Peptides were synthesized using Fmoc strategy and purified by preparative HPLC. They were characterized further by analytical HPLC and mass spectroscopy. Peptides were synthesized with an NH2-terminal Cys residue. The following peptides were used: CS-1, CEILDVPST; LDV-oe4(1), CNVSLDVHRKA; LDVc~4(2), CSFLLDVSSLS: LDV-o~4(3), and CFNVLDVQTTT. For control, the peptide VAIYDDMESLPLTGT was used. Peptide-346 carrier protein conjugates for cell adhesion were produced by crosslinking N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP)-activated rabbit IgG with peptides (39, 40) . The following peptides were conjugated: CS-1, CDELPQLVTLPHPNLHGPEILDVPST; LDV-o~4(1), CVLFYNVSLDVHRKAESPSRF; CMFSTKSAW-LRNGGADQGPRG (cr signal peptide) was used for control purpose. Peptide-carrier conjugates were coated to glass slides as described below.
Cytofluorography. The staining of cells with hybridoma supernatant-and PE-conjugated goat antibodies to rat immunoglobulins (SERVA, Heidelberg, FRG) has been described in detail elsewhere (41) . Stained cells were analyzed with a FACScan | fluorescenceactivated cell analyzer (Becton Dickinson, Heidelberg, FRG).
A~nity Purification of Cell Su[face Antigei~s. mAbs were coupled to CNBr-activated Sepharose (Pharmacia) and used for the purification of antigen by affinity chromatography as previously described (42) . Briefly, cells (ESb lymphoma, TK-1 cells, or pooled thymocytes and splenic lymphocytes) were lysed in 20 mM Tris/HC1, pH 8.0, containing 2% NP-40, 150 mM NaC1, 1 mM PMSF (lysis buffer). Lysates were cleared by centrifugation and passed over a normal rat IgG-Sepharose column followed by the specific antibody column. The column was washed with lysis buffer followed by buffer I (20 mM Tris/HC1, pH 8.0, 500 mM NaC1, 0.2% NP 40) and buffer II (20 mM Tris/HC1, pH 8.0, 0.05% NP-40). Subsequently, the column was washed with buffer III (50 mM Tris/HC1, pH 8.0, 150 mM NaC1, 50 mM 3-octylglucoside [BOG]) and then eluted with 100 mM diethylamine/HC1, pH 11.5, 150 mM NaC1 containing 50 mM BOG. Peak fractions of the eluate were neutralized and analyzed by SDS-PAGE after labeling with 12si using Iodobeads (Pierce, Oud-Beijerlandt, The Netherlands) or by silver staining. VCAM-1 and ICAM-1 were isolated by affinity chromatography from lysates of spleen, liver, and kidney of animals treated with TNF-o~ for 16 h.
Cell-binding Assay. Isolated antigen in BOG was diluted 1:10 to 1:30 with 10 mM Tris/HC1, pH 8.0, 150 mM NaC1 and coated to Labtek glass chamber slides (Nunc, Wiesbaden, FRG) for 16 h at 4~ Fibronectin (Sigma) in PBS was coated at a concentration of 10 #g/ml for 16 h at 4~ Wells were blocked with 2% BSA in PBS or 1% OVA in TBS for 2 h at room temperature, washed with HBSS containing 10 mM Hepes, 2 mM Ca 2+, and 2 mM Mg ~ § (binding buffer), and used for the assay. For binding, cells (5-10 x 106/ml) were suspended in the same buffer and 0.2-ml aliquots were added to the coated slides. The binding assay was performed for 30 min at room temperature without shaking and the slides were fixed in 2% glutaraldehyde/PBS after briefly dipping into PBS. For antibody-or peptide-blocking studies, cells were preincubated with purified antibody (40 #g/ml final concentration or as otherwise indicated) or peptides (150/zg/ml or otherwise indicated) for 10 min at room temperature and then transferred to the chamber slides. In some experiments, cells and coated slides were incubated separately with antibody and then washed before the experiment. Cation dependence was determined by preincubation of cells with 5 mM EDTA or 5 mM EGTA in HBSS with 10 mM Hepes for 10 rain and then used for the assay. For Mn 2 § activation, the Ca 2 § and Mg 2+ ions in the buffer were substituted with 0.5 mM Mn 2 § For PMA activation, the cells were incubated in 50 ng/ml PMA for 10 rain before the assay. Cell binding was measured by counting six independent fields at a magnification of 10 by video microscopy using IMAGE 1.47 software.
Biochemical Analysis. Lactoperoxidase-catalyzed iodination of surface glycoproteins on intact cells, cell lysis in the presence of NP-40, immunoprecipitation using protein G-Sepharose or protein A/MAR, treatment of precipitates with endoglycosidase F/Nglycosidase F (Boehringer Mannheim, Mannheim, FRG) has been Homophilic Binding of a4 Integrins described elsewhere (41) . SDS-PAGE was performed on 10% slab gels. Peptide mapping was carried out as described (43) . Briefly, iodinated 80-, 70-, and 34-kD fragments, respectively, were electrophoretically separated, eluted from the gel, and digested with papain (2/~g/ml) in 125 mM Tris/HC1, pH 6.8, containing 0.5% SDS, 10% glycerol, and 0.0001% bromphenol blue for 2 h. Digestion was stopped by boiling, and 2-ME and SDS were added to a final concentration of 10% and 2%, respectively. The samples were separated on a 15% SDS-PAGE. Gels were dried and exposed to x-ray-sensitive films (Kodak X-Omat; Siemens, Mannheim,
FRG).
R.esults mAb 5/3 is Specific for the or4 Subunit. mAb 5/3 was produced by immunizing rats with activated bend3 endothelioma cells. The antibody was initially selected because of its ability to block the binding of thymocytes to the activated endothelioma cells, mAb 5/3 stained the endothelioma cells and also reacted with lymphocytes in FACS | analysis (Becton Dickinson). Functional studies showed that the antibody not only blocked the binding of lymphocytes to endothelioma cells but also to fibronectin. This observation suggested that it might react with ct4 integrins. Biochemical analyses with the antibody were carried out using 125I surface-labeled ESb lymphoma cells. These cells express c~4 and an unknown/3 chain. Fig. 1 A (lane I ) shows that mAb 5/3 precipitated a major band of "~150 kD and two additional bands of 80 and 70 kD. The 150-kD band represents the intact a4 chain and the smaller bands are proteolytic cleavage fragments of the a4 chain that exist in the membrane (44, 45) . A/3 chain is not visible under the solubilisation conditions since in the mouse, the cx4/3 heterodimers are not stable in the absence of Ca 2+ and Mg z+ ions (13, 46) . Treatment of the precipitate with endoglycosidase F (Endo F) to remove N-linked glycans decreased the apparent mass of the bands to 92, 60, and 50 kD, respectively (lane 2). The 7/1 control antigen was reduced from "~50 to 34 kD after Endo F treatment (lanes 3 and 4). Additional experiments indicated that mAb 5/3 and the established cx4-specific mAb PS/2 precipitated identical protein bands from ESb ceils (lanes 5 and 6). Both mAbs were also compared for their ability to precipitate o~4 integrins from TK-1 cells (tx4/37) that were solubilized in the presence of Ca 2+ and Mg 2+ ions. Under these conditions, both mAbs showed the expected ix4 chains plus the/37 chain (lanes 8 and 9) that migrated at "~130 kD under nonreducing conditions. Fig. 1 B shows that mAb 5/3 stained TK-1 cells (c~4/37) and L1-2 cells (tx4/31) similar to mAb PS/2. In contrast to PS/2, which cross-reacts with human o~4 integrins, the mAb 5/3 did not stain human PBLs, suggesting that the two antibodies reacted with different epitopes on the cx4 chain.
To localize the mAb 5/3 epitope on the ix4 subunit, the tx4/37 heterodimer was isolated from iodinated TK-1 cells using mAb PS/2 bound to protein G. After washing, the bound antigen was eluted at pH 11.5, neutralized, and reprecipitated using mAb 5/3-Sepharose or control-Sepharose. The Purified or4 Sub'unit Binds Lymphocytes. We investigated whether the isolated ct4 subunit could bind cells. The antigen was isolated on a mAb 5/3-Sepharose column initially from ESb lymphoma lysate and the washing steps were carried out in the absence of Ca 2+ and Mg z+ ions to favor loss of the 13 chain. Bound material was eluted at pH 11.5 and the individual fractions were tested in ELISA. Antigen containing fractions were strongly reactive with mAb PS/2 to the ix4 subunit (not shown). When the peak fraction was iodinated and reanalyzed by SDS-PAGE, the expected bands of 150, 80, and 70 kD were seen for the or4 subunit (see Fig.  1 C, lane 1 ). In addition, minor bands at ~60, 46, and 34 kD, respectively, were observed. These bands were not detectable in the control antigen (7/1) obtained from the same lysate ( Fig. 1 , C, lane 2), suggesting that they represented most likely degradation products generated during the elution procedure (see also discussion of the 34-kD band below).
The affinity-purified c~4 subunit was coated to glass slides in increasing amounts and residual binding sites were blocked. As shown in Fig. 2 A, thymocytes adhered to the immobilized c~4 subunit in a concentration-dependent fashion. No binding was seen to the control antigens 7/1 (Fig. 2 A) or HSA (see Fig. 2 B) isolated from the same lysate. As illustrated in Fig. 2 B, high levels of binding were observed with resting T lymphocytes or Con A-activated T cell blasts.
To rule out the possibility that small amounts of B chain were copurified under the isolation conditions, the ct4 subunit was also isolated from the tx4/37-positive TK-1 cells since antibodies to the B7 chain are available. The 5/3 column-eluted material could also promote cell binding and revealed in ELISA a strong reactivity with mAb PS/2 but not with the/37-specific mAb Fib 30 (15) or with mAb DATK32, respectively, recognizing a combinational epitope of the ix4 and 137 subunit (17; data not shown).
Integrins Are Involved in the Binding to the or4 Subunit. Fig.  3 shows that the binding of thymocytes to the or4 subunit was cation dependent since pretreatment of the cells with EDTA or EGTA abolished binding. It was fully restored when Ca 2+ and Mg 2+ ions were added back to the assay (data not shown). Incubation at 4~ also inhibited adhesion. The binding of cells was enhanced by pretreatment with PMA and Mn 2+. The adhesion of thymocytes to fibronectin (Fig.  3) paralleled the binding to the or4 subunit and was equally affected.
The divalent cation requirement and temperature dependency suggested that the binding to the ix4 subunit might involve integrins. To further support this conclusion, we tested ol4-positive or c~4-negative cells for their ability to bind. The T cell hybridoma BI 141 and the T lymphoma Eb do not express or4 integrins, as shown by FACS | staining with mAbs PS/2 or 5/3, respectively. We compared the binding of these 347
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cells with TK-1 (ol4~7 +) and L1-2 (~4~1 § cells. As shown in Fig. 4 , both TK-1 and L1-2 cells adhered well to the c~4 subunit, the binding being further increased after PMA pretreatment. In contrast, BI 141 and Eb cells showed low level binding that was slightly enhanced after pretreatment of the cells with PMA but remained low (Fig. 4) . Human PBL bound weakly to the c~4 subunit. The binding was, however, strongly enhanced after PMA treatment of the cells (Fig. 4) .
Inhibition of Binding in the Presence of cr4-specific Antibodies.
Fig. 5 A shows that antibodies to LFA-1 or to CD45 did not effect the celt binding to the or4 subunit. In contrast, antibodies PS/2 and R1-2 directed against o~4 integrins were potent inhibitors, Similar blocking with ot4-specific antibodies was observed when resting T lymphocytes or TK-1 cells instead of thymocytes were studied (data not shown). mAb 5/3 also blocked the binding of thymocytes to the purified ol4 subunit in a dose-dependent manner (Fig. 5 B) . To determine whether the blocking effect occurred at the immobilized or4 subunit or at the cell surface, the coated glass slide and the cells were preincubated separately with mAb 5/3 and then washed to remove the antibody. As shown in Fig. 5/3 , preincubation of cells with mAb 5/3 blocked cell binding to the cr subunit. Also the binding to fibronectin was fully blocked (not shown). Preincubation of the c~ subunit coated to the glass slide did not affect the binding of cells (Fig. 5 B) . This suggested that in order to block, the antibody had to first bind to the lymphocyte cell surface. The data also indicated that two distinct epitopes on the c~4 chain existed: a binding epitope that can be blocked by mAb 5/3 and an attachment epitope(s) that is not blocked by this antibody.
The binding of human PBLs to the o~4 subunit was blocked in the presence of mAb PS/2 (which cross-reacts with human cells) but not mAb 5/3 (data not shown). This is in agreement with the observation that mAb 5/3 does not crossreact with human cells (Fig. 1 B) . 
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Homophilic Binding of c~4 Integrins Characterization of an or4 Chain Fragment. Upon prolonged storage, we noticed that the isolated c~4 subunit was degraded, yet could still mediate cell binding when coated to glass slides.
When bound and reeluted from the mAb 5/3 column, the material retained the ability to bind cells. We therefore purified conditions. The 34-kD protein migrated at '~25 kD under nonreducing conditions that implicated the presence of intrachain disulfide bridges (not shown). It could be reprecipitated as expected with mAb 5/3-Sepharose (Fig. 7 B, lane  3) but not by control antibodies coupled to Sepharose (lanes 2, 4, and 5), suggesting that it was a fragment of the cz4 subunit. The NH2 terminus of the 34-kD fragment was blocked. To determine the location within the oL4 subunit, peptide mapping analyses were carried out (Fig. 7 C) fragment were excised from the gel and digested with papain. Gel analysis of the digested material showed shared bands in the 80-and 34-kD fragments, respectively, which were absent in the 70-kD fragment (Fig. 7 C) . These results suggested that the 34-kD fragment was derived from the 80-kD portion of the cz4 molecule. This assignment is consistent with the localization of the mAb 5/3 epitope on the 80-kD subfragment (see Fig. 1 D) . When the ceU-binding ability of the intact oe4 subunit and the 34-kD fragment were compared, no differences were observed. Also, the binding to the fragment was blocked by cz4-specific antibodies and it required the presence of c~4 integrins on the cell surface. Thus, the 34-kD fragment had retained the mAb 5/3 epitope and the attachment epitope involved in cell binding.
The Fragment Blocks ol4 Integrin-dependent Cell Binding.
The 34-kD fragment was soluble in PBS and was studied for its potential to block ot4-dependent cell binding. In the presence of 2 #g/ml of the fragment the binding of thymocytes to fibronectin was inhibited by 60 _+ 3%, the binding to purified VCAM-1 by 43 _+ 5% (mean of three experi-
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Homophilic Binding of oe4 Integrins ments). Binding of thymocytes to the or4 fragment itself was blocked by >90% under these conditions, whereas the binding to purified ICAM-1, which is LFA-1 mediated, was not affected.
The cr4-subunit Contains LDV Peptide Motifs. The ability of the fragment to partially block the binding to VCAM-1 and fibronectin prompted us to search for structural similarities between the oe4 subunit and its ligands. The LDV peptide sequence within the CS-1 peptide of fibronectin was shown to be the minimal sequence to promote oe4~/1-mediated cell binding (39, 47) . Related sequences like IDS or LDT appear to be important in the binding to VCAM-1 or MAdCAM-1, respectively (48-51; Briskin, M. J., and E. C. Butcher, manuscript submitted for publication). We used these amino acid motifs to screen the mouse oe4 sequence. As shown in Table 1 , the ol4 subunit contains three LDV motifs that are conserved in the human oe4 sequence. The LDV-oe(1) is likely to be shared between the intact subunit and the 34-kD fragment.
Peptide-mediated Inhibition of Cell Binding. To test whether
the LDV sites were important in the cell binding to the oe4 subunit, peptides covering all three LDV sites were synthesized and used for inhibition studies. Fig. 8 A shows that at 150 #g/ml, the LDV-c~4(1) peptide was the only peptide that could efficiently inhibit the binding of thymocytes to the 34-kD fragment. The CS-1 peptide from fibronectin could also block the cell adhesion; however, it required approximately fivefold higher concentration. Similar results were observed when the intact or4 subunit was used as substrate (data not shown). A mixture of the LDV-ce4 peptides could partially block the adhesion of thymocytes to fibronectin (Fig.  8 B) . The binding to fibronectin was also inhibited by CS-1 peptide, as well as by mAb 5/3. The degree of inhibition seen with both reagents suggested that VLA-5, beside oe4 
Altevogt et al. (1) peptide, and a negative control peptide were coupled to rabbit IgG, coated to glass slides, and tested for the binding of thymocytes as described in Materials and Methods.
integrins an additional fibronectin receptors on thymocytes (52) is either not active or present in too low amounts to contribute to the binding.
The LDV-ot4 Peptide Promotes Cell Binding. To demonstrate binding of cells to the LDV-oz4(1) site, the peptide CVLFYN-VSLDVHRKAESPSKF was conjugated to rabbit IgG as carrier and was analyzed for its cell-binding capacity. As shown in Fig. 8 C, the LDV-c~4 peptide was as potent as the CS-1 peptide in promoting cell adhesion. A control peptide-IgG or rabbit IgG alone had only little or no effect.
Discussion
The ol4 integrin ligands comprise a diverse group of molecules with different structure and location. VCAM-1 and MAdCAM-1 belong to the Ig superfamily, whereas fibronectin is a plasma and extracellular matrix component. Invasin, another o~4 integrin-binding protein, is an outer membrane protein of Yersinia pseudotuberculosis that uses/31 integrins, including VLA-4 on human T cells as a receptor to enter the cell (53, 54) . In this report, we demonstrate that the c~4 subunit itself can be a ligand for or4 integrin-dependent lymphocyte binding.
Our studies were initiated by a novel mAb against 0~4 integrins, which was obtained by immunizing with the brainderived endothelioma bend3. The identification of such an antibody was not surprising since bend3 cells could be stained with mAb PS/2 and o~4 integrins can be detected on brain endothelial cells in vivo (Engelhardt, B., and E. C. Butcher, unpublished data). Studies using the novel mAb 5/3 in comparison to the established mAb PS/2 indicated that both antibodies recognized the o~4 chain and that the epitope for mAb 5/3 was located on the NH2-terminal 80-kD fragment of the oe4 subunit.
To investigate the functional ability of the c~4 subunit, we used the mAb 5/3 for affinity purification of the antigen from cell lysates. Surprisingly, when immobilized to glass slides, the purified o~4 subunit could avidly bind thymocytes or various lymphoid cell populations, whereas control antigens isolated from the same lysate could not. The cell adhesion was temperature dependent, required divalent cations, and was enhanced by PMA or Mn 2+ ions, suggesting that integrins were involved. Antibody-blocking studies demonstrated that mAbs to or4 integrins but no other antibodies were capable of inhibiting the binding to the ol4 subunit. Both ot4/$7-and c~4fll-positive mouse cells but also human peripheral blood lymphocytes could bind to the c~4 chain, whereas ol4-negative cells could not. Binding was also seen to a 34-kD soluble fragment derived from the c~4 subunit. Biochemical data indicated that it was derived from the 80-kD portion of the ol4 subunit. The requirements for the binding to the fragment were similar to the intact ol4 chain. This observation ruled out the possibility that the cell binding was mediated by residual intact o~3 heterodimers in the oL4 preparations. Based on the amount of protein, the fragment was as active as the intact o~4 subunit, indicating that it had retained a cell attachment site(s) that was present in the c~4 subunit. The fragment could block o~4 integrin-dependent binding of thymocytes to VCAM-1 and fibronectin but did not impair the binding of thymocytes to ICAM-1, which is LFA-1 dependent. The cross-blocking results suggested the involvement of a structurally related epitope in the binding of c~4 integrins to its ligands.
Binding of c~431 integrins to fibronectin involves the fibronectin CS-1 peptide, located in the alternatively spliced type III connecting segment (1-3, 39, 47) . The LDV amino acid motif is the minimal sequence that promotes oL4-dependent cell binding (39, 55) . As shown in Table 1 , homologous sequences to LDV are present in mouse and human VCAM-1. Mutation analysis of VCAM-1 in this position has shown that a D-A exchange introduced into the IDS sequence abolished the binding of o~4 integrins (48 (56) , suggesting that the LDV epitope can act independently of its environment. We analyzed the or4 subunit for similar binding motifs. The sequence analysis of the mouse or4 subunit revealed three LDV sites that are also present in the human or4 subunit but are not found, for example, in the or6 sequence. To analyze whether these sites were relevant for the binding, we initiated peptide inhibition studies. Based on these results, the LDV-ot(1) site appeared to be functionally most active. At higher concentrations (>500 gg/ml), the CS-1 peptide was also able to block the binding to the e~4 subunit in a specific fashion, supporting the notion that the LDV motif could indeed be important. Moreover, the LDV-ot(1) site, when coupled to IgG carrier protein, was as potent as the fibronectin CS-1 peptide in promoting cell binding. Thus, the c~4 integrin chain contains a potent cell-binding motif with the potential to support adhesion oflymphocytes through cell surface or4 integrins. It is presently unknown whether this ability is also preserved in the intact or4 integrin heterodimer. Although our studies do not address the potential importance of conformational alterations that might be induced during isolation and coating, it should be pointed out that little is known about the range of states assumed by or4 integrins expressed on the cell surface; the existence of free c~ chains has been suggested based on studies of cell lines expressing or4 in the absence of known or detectable novel pairing/3 chain (18, 57) . Recently, Weissman and colleagues have reported that transfection of c~4 into a/31-expressing melanoma cell results in enhanced cell-cell interactions in an assay involving adhesion of suspended B16 melanoma cells to an adherent melanoma monolayer (58) . Enhanced adhesion was dependent on or4 expression on both the suspended and monolayer populations, leading to the hypothesis that c~4 integrins might in this setting participate in homotypic molecular interactions. Our study demonstrating that the o~4 integrin chain itself contains motifs capable of serving as potent or4 integrin binding ligands is consistent with this model, and it raises the possibility that regulated ot4/31 and ol4/37 interaction with cell surface or4 represents an important new pathway for the control of cell-cell interactions. Formal proof of the involvement of or4 as a ligand in particular cell-cell adhesion events must await mutagenic analysis, permitting expression of or4 integrins displaying recognition but not ligand activity, or vice versa.
In summary, this paper characterizes a novel ligand for or4 integrins, namely the or4 subunit itself. It will be important to determine under what physiological conditions or4 is available as a ligand for cell-ceU interactions, and whether this activity can be regulated coordinately or independently of conventional or4 integrin functions. In conjunction with the recent evidence that or3 integrins can interact in a homotypic fashion (59), our results suggest a novel mechanism by which integrins may participate in the complex regulation of cell-cell interactions.
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